Dracen Pharmaceuticals, Inc.

San Diego, CA · Founded 2016 · CIK 0001728955 · Biotech · Public

small-molecule cancer therapeutic drug DRP-104

dracenpharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$19M
3 Form D · Aug 2023
38 months since last filing
Contracts
—
No federal contracts on record
Patents
10
4 granted · 6 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$8,488,896
Private capital raisedForm D · SEC$8,584,398
Private capital raisedForm D · SEC$2,285,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1853TBC I LLC—$1.0M
1854InCarda Therapeutics, Inc.—$66M
1855Recombinetics, Inc.—$45M
1856Dracen Pharmaceuticals, Inc.—$19M
1857Ibex Investment Holdings II LLC—$1.0M
1858Purinomia Biotech, Inc.—$10M
1859Apollomics Inc.—$10M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Dennis BilskiExecutive Officer
  • Thomas EstokDirector · Executive Officer
  • Robert JacksonDirector
  • Jonathan LeffDirector
  • Drew Pardoll, M.D., Ph.D.Director
  • Asher RubinExecutive Officer

Patents

USPTO · 4 granted of 10

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.